Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Sakr RA, Schizas M, Carniello JV, K Y Ng C, Piscuoglio S, Giri D, et al. Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. Mol Oncol. 2016;10(2):360-70.

Cantalupo A, Di Lorenzo A. S1P Signaling and De Novo Biosynthesis in Blood Pressure Homeostasis. J Pharmacol Exp Ther. 2016;358(2):359-70.

Testo N, Olson LC, Subramaniyam S, Hanson T, Magro CM. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas. Am J Dermatopathol. 2016;38(10):769-74.

Inayat F, Law JK, Myers-Gurevitch PM, Seshan SV, Perlman AS. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma. Clin Nephrol. 2016;85(3):184-8.

2015

Yigit N, Wu WW, Subramaniyam S, Mathew S, Geyer JT. BCR-PDGFRA fusion in a T lymphoblastic leukemia/lymphoma. Cancer Genet. 2015;208(7-8):404-7.

Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, et al. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Ann Hematol. 2015;94(11):1875-83.

Hoda S, Rao R, Hoda RS. Breast implant-associated anaplastic large cell lymphoma. Int J Surg Pathol. 2015;23(3):209-10.

D'Alfonso TM, Moo T-, Arleo EK, Cheng E, Antonio LB, Hoda SA. Cystic Neutrophilic Granulomatous Mastitis: Further Characterization of a Distinctive Histopathologic Entity Not Always Demonstrably Attributable to Corynebacterium Infection. Am J Surg Pathol. 2015;39(10):1440-7.

Mathieu R, Klatte T, Margulis V, Karam JA, Rouprêt M, Seitz C, et al. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol. 2015;33(11):495.e15-22.

Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, M Y Wang V, et al. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discov. 2015;5(6):636-51.